Table 4.
Baseline characteristics of patients with COVID-19 history
| Characteristics | Persistent seroconversion | No persistent seroconversion | P-value |
|---|---|---|---|
| (n = 11) | (n = 8) | ||
| Age (years), median (IQR) | 57.8 (45.7–73.6) | 72.1 (68.3–78.6) | 0.03 |
| Male, n (%) | 8 (72.7) | 4 (50) | 0.3 |
| BMI (kg/m2), median (IQR) | 27.3 (23.3–31.1) | 25.5 (20.7–37.5) | 0.26 |
| DN and/or nephroangioslcerosis, n (%) | 3 (27.3) | 1 (12.5) | 0.16 |
| Glomerulonephritis, n (%) | 1 (9.1) | 5 (62.5) | |
| Autosomal dominant polycystic kidney disease, n (%) | 1 (9.1) | 0 | |
| Tubulo-interstitial nephropathy, n (%) | 2 (18.2) | 1 (12.5) | |
| Indeterminate nephropathy, n (%) | 4 (36.4) | 1 (12.5) | |
| Blood group, n (%) | 0.4 | ||
| O | 2 (20) | 2 (25) | |
| A | 5 (50) | 2 (25) | |
| B | 2 (20) | 4 (50) | |
| AB, missing value (n = 2) |
1 (10) |
0 | |
| Dialysis vintage (years), median (IQR) | 3 (1.3–8.6) | 3 (1.3–5.8) | 0.5 |
| On steroids and/or immunosuppressants, n (%) | 0 | 0 | – |
| Diabetes, n (%) | 7 (63.6) | 5 (62.5) | 0.9 |
| Chronic respiratory disease, n (%) | 4(36.4) | 2 (25) | |
| Arterial hypertension, n (%) | 11 (100) | 5 (62.5) | 0.03 |
| Ischaemic/rhythmic cardiac disease, n (%) | 3 (27.3) | 4 (50) | 0.4 |
| Stroke, n (%) | 1 (9.1) | 1 (12.5) | 0.8 |
| Peripheral artery disease, n (%) | 3 (27.3) | 1 (12.5) | 0.4 |
| Cirrhosis, n (%) | 0 | 0 | – |
| History of or active cancer/transplantation, n (%) | 8 (72.7) | 6 (75) | 0.9 |
| Gamma globulin (g/L), median (IQR) | 11.9 (10–12.8) | 9.2 (6.1–11.4) | 0.07 |
| Lymphocyte count (×109/L), median (IQR) | 1.4 (0.9–1.7) | 1.1 (0.6–1.3) | 0.2 |
| Pre-dialysis β2-microglobulinaemia (mg/L), median (IQR) | 27.5 (22.7–32.1) | 22 (13.2–25.9) | 0.04 |
| Albumin (g/L), median (IQR) | 35.8 (32.3–39.1) | 34.7 (32.3–37.2) | 0.9 |
| CRP (mg/L), median (IQR) | 3.6 (1.7–18.9) | 3.1 (1.4–16.9) | 0.8 |
| History of symptomatic COVID, n (%) | 5 (45.5) | 3 (37.5) | 0.7 |
| Delay between COVID-19 diagnosis and vaccine (days), median (IQR) | 120.5 (87.5–239) | 275 (169.5–317.7) | 0.06 |
| HBV vaccine responders, n (%) | 6/6 (100) | 3/5 (60) | 0.18 |